News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News Scotland to fund BMS skin cancer combo Patient evidence convinces SMC Opdivo+Yervoy is cost-effective.
News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News UK aims to cut four years from drug development process NICE, regulator and NHS should work together, according to review.
UK & Europe NICE says Otezla's bargain price offsets lower efficacy Otezla cheap and convenient, but less effective than rivals, says NICE.
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
